New drug applications approved by US FDA as of 16 - 31 March 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Proton pump inhibitors (PPIs) may increase susceptibility to osteoporotic fractures in elderly women as compared with histamine-2 receptor antagonists (H2RAs), especially those who have used PPIs for at least a year, a recent study in Korea has found.
The addition of the epidermal growth factor receptor (EGFR) inhibitor cetuximab (CTX) to chemotherapy (CT) did not offer an overall survival (OS) benefit in patients with resectable colorectal liver metastasis (CRLM) compared with CT alone, updated results of the New EPOC trial has shown.
A triple fixed combination of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution provides superior intraocular pressure (IOP)-lowering effects compared with a dual fixed combination of brimonidine 0.2%/timolol 0.5% in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), according to the results of a phase III study.
The selective neurokinin 3 receptor antagonist fezolinetant induces rapid reductions in moderate-to-severe menopausal vasomotor symptoms (VMS) with a tolerable safety profile, according to the results of a phase IIb trial.
Patients with mild-to-moderate chronic kidney disease (CKD) may benefit from folic acid treatment, which helps reduce the likelihood of CKD progression, especially among those with high vitamin B12 levels, as shown in a study.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.
Pain is a multidimensional
experience that often requires a combination of various approaches to bring
about optimal outcomes. At a recent scientific symposium held during the 7th
Association of South-East Asian Pain Societies
Congress held in Yangon, Myanmar, Professor
Stefano Coaccioli discussed the evolution of ns-NSAIDs and how dexketoprofen
trometamol (Ketesse®; A. Menarini) can improve acute pain management.